Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatitis C virus nonstructural protein 5A (NS5A) is a multifunctional phosphoprotein essential for the viral life cycle, particularly in genotype 1a. Although it lacks intrinsic enzymatic activity, NS5A serves as a critical scaffold for the assembly of the viral replication complex and interacts with numerous host cellular proteins to modulate the environment for viral persistence (1.4.1, 1.4.2). It plays a dual role in the HCV life cycle: a cis-acting role in RNA replication and a trans-acting role in virion assembly and release (1.4.1, 1.5.1). NS5A is also a key factor in evading the host's innate immune response, specifically by inhibiting the interferon-induced protein kinase R (PKR) pathway (1.5.2, 1.5.3). As a primary target for direct-acting antivirals (DAAs), NS5A inhibitors like ledipasvir and velpatasvir are used in combination regimens to achieve high rates of sustained virologic response (1.2.4, 1.3.2). However, the high genetic variability of genotype 1a leads to the frequent emergence of resistance-associated substitutions (RAS), which can significantly reduce drug efficacy and persist in the viral population for extended periods (1.3.2, 1.3.4). These substitutions, such as M28V, Q30H/R, L31M/V, and Y93C/H/N, are critical biomarkers for guiding treatment selection and monitoring potential therapeutic failure (1.3.2, 1.3.3).
NS5A inhibitors bind to the N-terminal domain (Domain I) of the NS5A protein, likely interfering with its ability to form dimers or higher-order complexes. This disruption blocks the protein's essential roles in both the assembly of the viral replication complex (cis-acting) and the later stages of virion assembly and release (trans-acting).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis C virus nonstructural protein 5A (NS5A) (NS5A).